CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS
BEIJING, May 17, 2023 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2023. Wei-Wu He, Ph.D., CASI’s Chairman and Chief Executive Officer, commented, “Revenue for EVOMELA® was $8.3 million … Read more